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Abstract
Introduction—Few studies have examined age and racial/ethnic disparities in invasive breast 
cancer among younger (age 15–44 years) vs. older (age 45–64 years) women. This study estimates 
disparities in breast cancer among younger compared with older women by race/ethnicity using 
five measures of population health: life expectancy (LE), expected years of life lost (EYLL), 
cumulative incidence rate (CIR), and incidence and mortality rate ratios (IRR and MRR).
Methods—Using Surveillance, Epidemiology, and End Results data, LE and EYLL were 
estimated from a cohort of 15–44 and 45–64 years, non-Hispanic black (NHB), non-Hispanic 
white (NHW), and Hispanic women diagnosed with breast cancer, 2000–2013. Survival function 
was obtained from the study years and then extrapolated to lifetime using the Monte Carlo 
method. The CIR, IRR and MRR were calculated using 2009–2013 breast cancer incidence and 
mortality rates from the Centers for Disease Control and Prevention’s National Program of Cancer 
Registries.
Results—The estimated LE ranged from 32.12 to 7.42 years for localized to distant stages 
among younger NHB women compared to 33.05 to 9.95 years for younger NHW women. The 
estimated EYLL was 12.78 years for younger women, and 4.99 for older women. By race/
ethnicity, it was 15.53 years for NHB, 14.23 years for Hispanic and 11.87 years for NHW (P 
<0.00025). The CIR for age-group 15–44 years (CIR15–44 indicated a 1 in 86 probability for NHB 
compared to a 1 in 87 probability for NHW being diagnosed with breast cancer by age 45. The 
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estimated age-adjusted incidence rate for NHB-to-NHW women was IRR = 1.10 (95%, CI = 1.08–
1.11) and the corresponding mortality rate was MRR = 2.02 (95%, CI = 1.94–2.11).
Conclusions—The breast cancer disparities between younger NHB compared to NHW women 
highlight the need for expanded efforts to address these disparities through primary prevention and 
to improve access to quality healthcare to minority women with breast cancer.
Keywords
Breast cancer; Racial health disparity; Incidence and mortality; Survival; Life expectancy; and 
expected years of life lost
1. Introduction
Breast cancer is the most common malignant tumor among U.S. women, accounting for 
30% of incident cancers [1]. Despite the benefits of advances in treatment and early 
detection that have contributed to the decline in breast cancer deaths [2], not all age and 
racial/ethnic groups have benefited equally and disparities in incidence and mortality still 
exist [3]. Further, several studies have examined age disparities in breast cancer outcomes 
[4–9]. These studies have reported substantially lower health-related quality of life resulting 
from breast cancer treatment in younger (i.e., aged 15–44 years) compared with older (i.e., 
aged 45–64 years) women. Similarly, studies have reported racial/ethnic disparities in breast 
cancer outcomes [10–13]. These studies found that black women are more likely than white 
women to have late-stage breast cancer at diagnosis and have less favorable outcomes, 
including higher mortality rates [10,11]. In addition, other studies have also found that both 
younger and older black women have higher mortality rates than any other racial/ethnic 
group [12,13].
In recent years, there has been public health initiative in breast cancer among younger 
women. More specifically, the Education and Awareness Requires Learning Young 
(EARLY) Act, Section 10413 of the Affordable Care Act [Public Law 111–148]) [14] has 
renewed interest in how the risk of breast cancer impacts younger women. Currently, no 
studies have examined age (younger versus (vs) older) and racial/ethnic disparities (that is, 
non-Hispanic black (NHB), non-Hispanic white (NHW), and Hispanic women) using 
multiple measures of population health, which includes life expectancy (LE), expected years 
of life lost (EYLL), cumulative incidence rates for women ages 15–44 and 45–64 years 
(CIR15–44,45–64), and age-adjusted incidence and mortality rate ratios (IRR and MRR). 
However, the impact of breast cancer disparities have been quantified using other 
population-based measures developed to evaluate cancer progress in national health 
objectives [15–17].
In this paper, we utilized multiple measures of population health (i.e., LE, EYLL, CIR, IRR, 
and MRR), to determine 1) whether breast cancer burden was greater for younger vs older 
women; 2) to estimate the magnitude of racial/ethnic disparities in invasive breast cancer 
among younger NHB vs NHW women, and younger Hispanic vs NHW women; and 3) to 
examine whether racial/ethnic disparities in incidence and mortality of breast cancer among 
younger women are worse in breast cancer than in all other female cancers. Each of these 
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measures contributes differently in providing information to patients, clinicians, and health 
policy-makers on the burden of breast cancer disparities in age-and racial/ethnic-groups. We 
hope that the use of these measures may provide useful data for outcome assessment and 
resource allocation of health services and development of prevention strategies for age- and 
racial/ethnic-groups that are disproportionately more likely to develop breast cancer in their 
lifetime.
2. Methods
2.1. Data sources and study population
Data from the National Cancer Institute (NCI)’s 2000–2013 Surveillance, Epidemiology, 
and End Results (SEER-18) registries [18], which covers 28% of the US population, were 
used to estimate LE and EYLL. The SEER-18 registries were used because it contains 
survival information needed to estimate these measures [18]. A cohort of 88,406 women 
aged 15–44 and 345,025 women aged 45–64 with invasive breast cancer were identified 
from SEER. In addition, the combined dataset from the Centers for Disease Control and 
Prevention (CDC)’s National Program of Cancer Registries (NPCR) and the NCI’s SEER 
registries [1], which covers the entire U.S. population, were used to estimate CIRs, 
incidence, and mortality rates for a separate cohort of 113,328 women aged 15–44 and 
512,511 women aged 45–64 diagnosed (2009–2013) with invasive breast cancer. These 
population-based cancer registries collect detailed information on patient’s sex, race/
ethnicity, year of diagnosis, age of diagnosis, cancer site, stage, survival months, and vital 
status [18]. In both datasets, invasive breast cancer was defined by the standards in the 
International Classification of Diseases for Oncology, 3rd Edition [19]. To minimize 
confounding of survival times for the primary cancer, patients with a prior breast cancer 
diagnosis and those diagnosed based on death certificate or autopsy only were excluded 
(<1%). Death was defined as all-cause mortality; all breast cancer patients were followed 
until death or through the end of follow-up (December 31, 2013).
2.2. Measures of population health
The LE and EYLL incorporate data on the US life tables to estimate the burden of breast 
cancer in the population [20]. The estimation of LE from the date of diagnosis until death 
was used to generate lifetime survival in different racial/ethnic groups (NHB, NHW, and 
Hispanic) that may be relevant to clinicians in treating breast cancer patients. In estimating 
LE, we did not include racial/ethnic groups of Asian/Pacific Islander and American Indian/
Alaska Native women because of a lack of life tables for these populations.
On the other hand, the estimation of EYLL, which is a measure of the overall burden of 
disease was used to determine the lifetime health impact of breast cancer in age-and racial/
ethnic-groups. These two measures were used to examine the extent to which a younger 
NHB vs NHW, and younger Hispanic vs NHW woman’s life span was likely to be reduced 
by breast cancer after diagnosis. The third measure (CIR15–44,45–64) estimated age, and 
racial/ethnic disparities in the cumulative risk of being diagnosed with breast cancer over a 
time period and age interval [21] in the population. The last two measures, IRR and MRR, 
were used to further explore whether racial/ethnic disparity in incidence and mortality of 
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breast cancer among younger women are worse in breast cancer than in all other female 
cancers [22].
2.3. Calculation of life expectancy (LE)
The Kaplan-Meier method [23] was used to estimate survival function for each cohort of 
breast cancer patients with 14 years of follow-up. Using a semi-parametric method [24], the 
estimated survival functions were further extrapolated up to 720 months (60 years) to derive 
LE after breast cancer diagnosis. The method uses relevant external information to aid the 
survival extrapolation. Its technical details have been described elsewhere [25]. Briefly, for a 
breast cancer cohort, the US life tables [26] were used to generate survival times for an age-, 
sex- and race/ethnicity-matched reference population using a Monte Carlo method. 
Thesurvival times are then used for estimating survival function of the reference population. 
Second, with the assumption of excess constant hazard, logit transformation of the survival 
ratios between the cohort and the reference population will approach a straight line [27]. 
Hence, a linear regression was fitted to the logit transformed survival ratios during some 
time period near the end of follow-up. Finally, the estimated regression line and the survival 
function of the reference population beyond the follow-up limit were used to extrapolate the 
lifetime survival function of the cohort. The standard errors of the estimated LE were 
obtained using a bootstrap method.
2.4. Calculation of expected years of life lost (EYLL) per breast cancer patient
EYLL was defined as the reduced LE due to breast cancer in younger vs older women, 
younger NHB vs NHW women and younger Hispanic vs NHW women from that of the age- 
sex- and race/ethnicity-matched reference population. It was calculated by taking the 
difference in the areas under the long-term survival curves between the breast cancer cohort 
and the reference population as shown in Fig. 1a, b, and c.
2.5. Calculation of cumulative incidence rates (CIR15–44,45–64)
The CIR15–44,45–64 was calculated using the most recent five years of data (2009–2013) on 
breast cancer incidence rates among younger vs older women, younger NHB vs NHW 
women, and younger Hispanic vs NHW women from the NPCR/SEER registries [1]. The 
calculation of CIR15–44,45–64 was as follows: CIR15–44,45–64 = 1−exp [−Si (IRi) * (Δti)]; 
where IRi represents the age-specific incidence rate and Δti indicates the range of each age 
stratum.
2.6. Calculation of breast cancer incidence and mortality rate ratios (IRRs and MRRs)
Using the age-adjusted breast cancer incidence and mortality rates obtained from the 2009–
2013 NPCR-SEER registries [1], IRRs and MRRs for younger-to-older, younger NHB-to-
NHW and younger Hispanic-to-NHW women were calculated. We also calculated IRRs and 
MRRs for all other female cancer sites.
2.7. Statistical analysis
The methods described above for estimating LE and EYLL were conducted using the 
Integration of Survival with Quality of Life (iSQoL) statistical software [28]. Differences in 
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stage distribution and EYLL of breast cancer patients by age-groups and race/ethnicity were 
tested with chi-square test and one-sided z-tests, with P <0.05 as the level of significance. 
Further, SEER*Stat software (version 8.3.2) [29] was used to extract age- and race/ethnicity-
specific breast cancer incidence, mortality, and associated population data for the years 
2009–2013. Rates, expressed per 100,000 population, were directly age-adjusted to the 2000 
US standard population [30]. The age-adjusted IRRs and MRRs were also calculated using 
the age-adjusted rates for younger NHB vs NHW and younger Hispanic vs NHW women. 
We calculated 95% confidence intervals (CIs) for age-adjusted RRs based on methods 
described elsewhere [31].
3. Results
Table 1 presents the characteristics of invasive breast cancer by stage, age and race/ethnicity. 
Overall, the mean age at diagnosis for younger vs older women were 39.02 and 54.86 years, 
respectively. A significantly greater proportion of younger women (48.13%) were diagnosed 
at late stages (i.e., regional and distant) compared with older women (38.66%), P <0.0001. 
By racial/ethnic group, 54.49% of younger NHB women were diagnosed at late stage 
compared with 45.95% of NHW women, (P <0.0001). Similarly, younger Hispanic women 
had a higher proportion of late stage diagnosis (52.88%) compared with NHW women, P 
<0.0001 (Table 1).
3.1. Estimated LE and EYLL due to breast cancer
For all women, the estimated LE was higher for younger women, with 33.36, 26.47, and 
10.20 years for localized, regional, and distant stages, respectively, compared to estimates 
for older women, which were 26.26, 20.96, and 6.50 years for localized, regional, and 
distant stages, respectively, P <0.00025 (Table 2). The estimated LEs were shorter for 
younger NHB women (32.12, 22.01, and 7.42 years for localized, regional and distant 
stages, respectively than estimates for NHW women, which were 33.05, 28.77, and 9.95 
years for localized, regional, and distant stages, respectively. However, for younger Hispanic 
women the estimated LEs were longer than for NHW women in localized and distant stages 
(39.49 vs 33.05 and 12.17 vs 9.95 years), respectively.
Over a lifetime, younger women with breast cancer were estimated to have more life-years 
lost with an estimated EYLL of 12.78 years compared with 4.99 years for older women 
P<0.00025 (Fig. 1a). By racial/ethnic group, younger NHB women had more life-years lost 
with an estimated EYLL of 15.53 years compared with NHW women, (EYLL = 11.87 
years), P <0.00025 (Fig. 1b). Similarly, younger Hispanic women were more likely than 
NHW women to have greater life-years lost (EYLL = 14.23 vs. 11.87 year) (Fig. 1c).
By stage at diagnosis, the estimated life-years lost for all younger women were EYLL of 
8.83, 16.12, and 33.15 years for localized, regional and distant stages compared with 
estimates for older women of 1.83, 7.76, and 21.51 years for localized, regional and distant 
stages, P <0.00025 (Table 2). Younger NHB women’s EYLL was 7.89 and 18.42 for 
localized and regional stages compared with estimates for NHW women, EYLL were 9.30 
and 13.95 years for localized and regional stages (P <0.00025). The estimated EYLL was 
greater for younger Hispanic women than NHW women in regional and distant stages (20.36 
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and 33.96 years). These estimates indicate that in all stages at diagnosis, younger women 
have more significant years of life lost than older women. Similarly, younger NHB women 
experience significantly more years of life lost at regional stage; however at localized stage, 
younger NHW women have slightly higher years of life lost.
3.2. Estimated CIR15–44, 45–64 for breast cancer
Overall, the CIR15–44,45–64 for younger women during the time period 2009–2013 was 
estimated to be 0.0109 vs 0.0479 for older women (Table 2). The results imply that among 
women aged 15–44 years, 1 in 92 will be diagnosed with an invasive breast cancer compared 
to 1 in 21 for women age 45–64 years. In other words, 1.09% of younger women would 
develop an invasive breast cancer by age 45 and 4.79% of older women would develop an 
invasive breast cancer by age 65. By race/ethnicity, the CIR15–44 estimate for younger NHB 
women was 0.0116, indicating that 1 in 86 will be diagnosed with an invasive breast cancer 
compared to 1 in 87 for younger NHW women (CIR15–44 = 0.0115). For younger Hispanic 
women, the estimate was 0.0076 or 1 in 132 will be diagnosed with invasive breast cancer 
by age 45.
3.3. Incidence and mortality rate ratios
Table 3 presents the age-adjusted IRR and MRR among younger NHB-to-NHW women, and 
younger Hispanic-to-NHW women by breast cancer and all other female cancer sites. 
Among younger women, the breast cancer incidence rate was 10% higher for NHB than 
NHW (IRR = 1.10; 95% CI = 1.08–1.11) (Table 3). On the other hand, the incidence rate for 
all other female cancer sites was significantly lower in NHB compared with NHW women 
(IRR = 0.70; 95% CI = 0.69–0.70). In general, the racial/ethnic disparity in incidence rate 
was worse in breast cancer than in all other female cancers. In contrast, the estimated breast 
cancer incidence rate and the rate for all other female cancers were lower in Hispanic than 
NHW women (IRR = 0.73; 95% CI = 0.72–0.73 and IRR = 0.73; 95% CI = 0.72–0.73), 
respectively.
The estimated mortality rate for breast cancer was twice as high for younger NHB compared 
with NHW women (MRR = 2.02; 95% CI = 1.94–2.11). Similarly, the rate for all other 
female cancer sites was also higher for NHB compared with NHW women (MRR = 1.17; 
95% CI = 1.16–1.19). The disparity in mortality rate was worse in breast cancer than in all 
other female cancers. On the contrary, younger Hispanic women were significantly less 
likely than NHW women to die of breast cancer (MRR = 0.78; 95% CI = 0.73–0.82). A 
similar result was also observed in all other female cancers (MRR = 0.80; 95% CI = 0.79–
0.81).
4. Discussion
Using multiple measures of population health, there were significant age and racial/ethnic 
disparities among younger women across five measures of population health. Compared 
with older women, a significant proportion of younger women have more years of life lost 
and a greater occurrence of being diagnosed with breast cancer at late stages. However, 
younger women have a lower risk of developing breast cancer. Further, relative to younger 
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NHW women, a greater proportion of younger NHB women were diagnosed at late stages 
(i.e., regional and distant), had lower life expectancy, greater years of life lost, a higher 
probability of being diagnosed with breast cancer at an early age and a greater burden of 
age-adjusted incidence and mortality rates. Similarly, younger Hispanic women had a high 
rate of being diagnosed with breast cancer at late-stages, have a high proportion of years of 
life lost, but have less probability of being diagnosed with breast cancer as well as less likely 
to die from it compared with NHW women.
The findings from the use of these measures are consistent with previous literature on the 
age disparity [4–9,32] and is also consistent with previous work on the racial/ethnic disparity 
and confirms that NHB women experience a higher burden of disease from breast cancer at a 
younger age [4,10–13,33,34]. To our knowledge, there are no other studies that have 
quantified the burden of breast cancer in younger vs older women, younger NHB vs NHW 
women, and younger Hispanic vs NHW women using these multiple measures of health. 
Prior to this paper, most studies examined racial/ethnic disparities in breast cancer, but they 
did not make race/ethnic-specific comparisons between younger versus older women 
[10,11,35].
Currently, there are no studies that have quantified the burden of breast cancer in younger 
women using EYLL. However, compared with findings from older women, younger women 
experience greater years of life lost with an additional 7.79-year decrease in life span 
[24,36]. Consistent with shorter life expectancy observed among younger NHB women, the 
average years of life lost was greater for NHB and Hispanic than for NHW women, with 
NHB and Hispanic women experiencing an additional 3.36-year and 2.36-years decrease in 
life span.
We are not aware of any previously published estimates of CIR15–44 on breast cancer in 
younger women, but postulate that these estimates may increase in the future given recent 
studies reporting the increasing number of new cancer cases and widening disparities [37–
41]. The cumulative probability of breast cancer occurrence for women 15–44 years showed 
that more NHB women and fewer Hispanic than NHW women were diagnosed with an 
invasive breast cancer by age 45.
Estimates of IRR and MRR revealed significant disparities in incidence and mortality rates 
for breast cancer and in all other female cancer sites. These findings are consistent with 
previous reports [22,38–41] and a reminder that regardless of improvement in breast cancer 
survivorship, racial/ethnic disparities still persistent. The disparities in incidence may reflect 
the greater decline in incidence for white women than for black women. Among white 
women, this decline is partly due to decreasing use of hormone replacement therapy (HRT) 
[42]. Black women did not experience this level of benefit because their use of HRT was low 
[42]. Further, a recent study has found a convergence of incidence rates between black and 
white women [43]. As reported in this paper, incidence rates increased from 2009 to 2013 
for NHB women, while the rates for NHW women decreased. Further, breast cancer deaths 
for NHB women are expected to increase, which likely reflects the growing, aging 
population [44]. Many factors contribute to large mortality gaps. For instance, compared 
with white women, black women are more likely to be diagnosed at later stage as reported in 
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this paper and less likely to receive timely and high quality treatment at the time of diagnosis 
[35,45–51]. Further, compared with white women, black women are more likely to have 
tumor subtypes, especially the triple negative subtype, which have poorer prognosis [52–56]. 
Unlike younger black women, younger Hispanic women are less likely to be diagnosed and 
die from breast cancer than non-Hispanic White women. This finding is consistent with 
previous reports (40,42,60). However, there is a lot of variation within Hispanic subgroups 
and additional work is needed [57].
As demonstrated in this study, age and racial/ethnic disparities in breast cancer still remain. 
However, there have been efforts to address age- and racial/ethnic group disparities [58]. For 
example, the CDC has recently launch a multimedia, multi-pronged national campaign to 
educate younger women on the risk factors for breast cancer, encourage them to learn their 
family history of breast cancer, inspire them to talk to their healthcare provider if they think 
they might be at higher risk, and encourage them to live healthy lifestyles and be aware of 
their own breast health [59]. Given that these interventions are still in the nascent stages, the 
findings reported in this paper could be useful to inform decisions to effectively target 
populations with disproportionate burden of breast cancer. Additionally, the data reported in 
this paper could be used as inputs to conduct economic studies to evaluate the cost-
effectiveness of interventions designed to reduce breast cancer in younger women.
According to the Institute of Medicine, no single measure can sufficiently capture the health 
of the nation [60]. Therefore, the use of multiple measures of population health to quantify 
the magnitude of breast cancer disparities provides a more meaningful representation of the 
burden of breast cancer. Findings reported in each of these measures may be helpful for 
program planners and decision makers to inform allocation of resources and effectively 
target subgroups of the population with a disproportionate burden of breast cancer disease. 
More efforts are needed to detect cancer at an early, treatable stage and to ensure timely 
access to high quality treatment to reduce this disproportionate burden.
This study has some limitations. First, this study only provides estimates of the average loss 
of LE by cancer stage and did not consider other factors, such as comorbidity and disability, 
therefore, reported LE may be overstated [61,62]. Second, calculated CIR15–44 may be 
slightly overestimated because the approach assumes that the current risk estimates remain 
stable during the follow-up period (2009–2013) and the population under study is not 
subject to competing risk of death from other causes [63]. Finally, given that Hispanics are 
more likely to have incomplete follow-up for censored cases than whites or blacks in SEER 
dataset, estimates for Hispanic ethnicity should be interpreted with caution [64]. However, 
we used the active follow-up (reported alive method) to calculate their survival interval; 
hence Hispanics’ survival may not be overestimated.
In conclusion, there are substantial disparities in breast cancer between younger compared 
with older women, and younger NHB women compared with younger NHW women in the 
multiple measures of population health used in this study. This suggests that many younger 
women, especially NHB are disproportionately impacted by breast cancer compared to their 
counterparts. Expanded efforts are needed to understand how to better address these 
disparities through primary prevention and improve access to quality healthcare.
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Fig. 1. 
(a) Estimated expected years of life lost (EYLL) from breast cancer among younger women 
aged 15–44 years compared with older women aged 45–64 years, SEER registries, 2000–
2013.1 (b) Estimated expected years of life lost (EYLL) from breast cancer among younger 
non-Hispanic black (NHB) women compared with younger non-Hispanic white (NHW) 
women, SEER registries, 2000–2013.2 (c) Estimated expected years of life lost (EYLL) 
from breast cancer among younger Hispanic women compared with younger non-Hispanic 
white (NHW) women, SEER registries, 2000–2013.3
1The estimated EYLL was 7.79 years (= 12.78–4.99 years) was significantly different 
between younger and older women with P <0.00025
2The estimated EYLL was 3.66 years (= 15.53–11.87 years) was significantly different 
between younger NHB women vs. younger NHW women with P <0.00025.
3The estimated EYLL was 2.36 years (= 14.23–11.87 years) was significantly different 
between younger Hispanic women vs. younger NHW women with P <0.00025
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Table 3
Estimated age-adjusted incidence and mortality rate ratios in breast and all female cancer sites among younger 
womena by race/ethnicity, SEER and NPCR, 2009–2013.
Incidence rate ratios Mortality rate ratio
Race/ethnicity by younger women Race/ethnicity by younger women
15–44 years NHB: NHW 
RRb
15–44 years Hispanic: 
NHW RRc
15–44 years NHB: NHW 
RRb
15–44 years Hispanic: 
NHW RRc
(95% CI) (95% CI) (95% CI) (95% CI)
All other female 
cancer sites
0.70* 0.73* 1.17* 0.80*
(0.69–0.70) (0.72–0.73) (1.16–1.19) (0.79–0.81)
Breast 1.10* 0.73* 2.02* 0.78*
(1.08–1.11) (0.72–0.75) (1.94–2.11) (0.73–0.82)
NHW: Non-Hispanic White; NHB: Non-Hispanic Black; SE, standard error of mean; RR: rate ratio; CI: confidence interval; NOS: not otherwise 
specified; Rates are per 100,000 and age-adjusted to the 2000 US standard population (19 age groups – Census P25-1130) standard.
*
The rate ratio indicates that the rates are significantly different (P <0.05).
a
Younger women was defined as those aged 15–44 years.
b
The NHB-to-NHW ratio for younger women was the age-adjusted incidence and mortality rates for NHB women aged 15–44 years divided by the 
age-adjusted incidence and mortality rates for NHW aged 15–44 years, and age-adjusted incidence and mortality rates obtained from the 2009–
2013 NPCR (National Program of Cancer Registries) and SEER (Surveillance, Epidemiology, and End Results) registries.
c
The Hispanic-to-NHW ratio for younger women was the age-adjusted incidence and mortality rates for Hispanic women aged 15–44 years divided 
by the age-adjusted incidence and mortality rates for NHW women aged 15–44 years, and age-adjusted incidence and mortality rates obtained from 
the 2009–2013 NPCR and SEER registries.
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